Navigation Links
S*BIO's Novel JAK2 Inhibitor Pacritinib (SB1518) Effectively Reduces Splenomegaly in Myelofibrosis (MF) Patients With Minimal Impact on Existing Cytopenias Providing Important Therapeutic Niche In Treatment of MF
Date:12/12/2011

SINGAPORE, Dec. 12, 2011 /PRNewswire/ -- S*BIO Pte Ltd today announced that results from a Phase 2 study demonstrated that its JAK2 inhibitor pacritinib (SB1518) effectively reduced splenomegaly in myelofibrosis (MF) patients, with minimal impact on existing cytopenias providing an important therapeutic niche in the treatment of MF. Results were presented at the 53rd ASH Annual Meeting and Exposition in San Diego.

"Pacritinib is an active drug for the treatment of splenomegaly in patients with primary myelofibrosis, post-polycythemia vera-myelofibrosis and post-essential thrombocythemia-myelofibrosis regardless of baseline thrombocytopenia," said Rami S. Komrokji, M.D., principal author of the oral presentation. "The once daily dose of pacritinib was well tolerated with manageable gastrointestinal toxicity as the main side effect. The minimal impact on existing cytopenias in MF patients provides an important therapeutic outcome for pacritinib in the treatment of this patient population. The results support the rapid advancement of pacritinib into Phase 3 clinical trials to further support its safety and efficacy."

The primary endpoint of pacritinib's Phase 2 study was to assess the spleen response rate, defined as a >/=35% reduction in MRI-measured spleen volume between baseline and week 24. Thirty-four MF patients were enrolled in the study. The most common treatment-related adverse events were gastrointestinal, which were generally low grade and easily managed.  Pacritinib was equally well tolerated by patients with normal platelet counts and those with thrombocytopenia and anemia. Thirty patients (88%) showed reduction in palpable splenomegaly, 14 (41%) showed decreases of >/=50% and five (15%) achieved clinical resolution of splenomegaly. Eight patients (24%) had decreases in spleen volume by >/=35%.  Spleen response rates were equivalent among patients with low baseline platelet counts and those with normal baseline cou
'/>"/>

SOURCE S*BIO Pte Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. University Hospitals Seidman Cancer Center Tests Novel Drug That Makes Brain Tumors Glow Hot Pink
2. Novelos Therapeutics Prices $5.9 Million Public Offering
3. MacroGenics and Servier Enter Development and Commercialization Agreement for Novel Anti-Cancer Drug
4. Unigenes Proprietary Peptelligence™ Platform Used to Commence Cara Therapeutics Phase 1 Clinical Trial of Oral Novel Peripherally-Acting Kappa Opioid Agonist
5. New Study Points to Novel Mechanism by Which Tumors Escape Recognition by the Immune System
6. Cara Therapeutics Initiates Phase I Study with Oral Formulation of Novel Peripherally-Acting Kappa Opioid Agonist
7. Niiki Pharma Reports on Synergistic Activity of Novel Anti-Cancer Agent NKP-1339 with Other Anti-Cancer Agents
8. CureFAKtor Pharmaceuticals Demonstrates Novel Focal Adhesion Kinase (FAK) Inhibitor C4 Analogs Inhibited Pancreatic Cancer Tumor Growth as Single Agents
9. Childrens Hospital Boston and Pfizer Enter Into Novel Collaborative Research Agreement for Muscular Dystrophy Therapeutics
10. ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis
11. Metabolex to Present Data on Arhalofenate, a Potential Novel Treatment for Gout, at the 2011 ACR/ARHP Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  Drug delivery technologies that ... essential part of the entire drug development process. ... in new vaccine delivery technologies in a bid ... skin delivery procedures. New analysis from ... though the needle-free delivery sector currently makes up ...
(Date:9/2/2014)... COSTA MESA, Calif. , Sept. 2, 2014 ... organization was just recognized as one of the ... Over the past few years, the company has ... phase clinical research, late phase global clinical development, ... the past 2 years, WCCT Global has successfully ...
(Date:9/1/2014)... YORK , Sept. 1, 2014 ... market research report is available in its catalogue: ... 2014 - 2024 http://www.reportlinker.com/p02280919/Antibody-Drug-Conjugates-Market-2nd-Edition-2014---2024.html ... (ADCs) are a new class of therapeutic agents, ... pharmaceutical companies. Generally addressed as the marriage of ...
Breaking Medicine Technology:Needle-Free Delivery Devices Shape the Future of Vaccines, Says Frost & Sullivan 2Needle-Free Delivery Devices Shape the Future of Vaccines, Says Frost & Sullivan 3Contract Research Organization WCCT Global Celebrates Being Named as One of the Fastest Growing Companies in America 2Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 2Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 3Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 4Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 5Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 6Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 7Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 8Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 9Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 10Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 11Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 12Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 13Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 14Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 15Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 16Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 17Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 18
... USCAP MeetingSOUTH SAN FRANCISCO, Calif., March 13 Rigel ... the enrollment of the first patient in a Phase ... patients with refractory or relapsed peripheral T-cell lymphoma (PTCL). ... the efficacy of R788, an orally bio-available Syk kinase ...
... Phase II Study Published in The Lancet of Fast-Tracked ... Minor Bleeding and was Well Tolerated When Given With ... a Schering-Plough Corporation (NYSE: SGP ) Phase ... receptor antagonist (TRA), were published today in The ...
Cached Medicine Technology:Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas 2Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas 3Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 2Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 3Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 4Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 5Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 6Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 7
(Date:9/2/2014)... The Jerry Segal Classic to benefit ... 19 at The ACE Club and Green Valley Country ... years, the Classic, organized by the Friends of Jerry ... and services designed to support patients and their families ... “The Segal Classic is a labor of love, my ...
(Date:9/2/2014)... Port Washington, New York (PRWEB) September 02, 2014 ... Waichman LLP announces that Class Counsel has ... and for service awards in the class action ... to Parker Waichman LLP, the Court-Appointed Class Counsel ... Cabraser Heimann & Bernstein, LLP; Audet & Partners, ...
(Date:9/2/2014)... 2014 Lseat.com is one of the most ... its products are user-friendly items; no professional installation is required. ... they can slip right over the cars’ seats. That can ... website is filled with various kinds of practical covers. ... of Jeep leather seat covers . Also, the company ...
(Date:9/2/2014)... California (PRWEB) September 02, 2014 The ... reach USD 8,918.8 million by 2020, growing at an ... to a new study by Grand View Research, Inc. ... and plague modification devices are used for treating peripheral ... formation of atherosclerotic plaques in arteries. These devices are ...
(Date:9/2/2014)... 2014 Eric Jimenez and Leah Ashley ... a revolutionary makeup application device. Designed to improve and ... in the palm of women’s hands to help them ... Color Me’s success lies in its patented technology. With ... of 15,000 pulses per minute, the device applies foundation ...
Breaking Medicine News(10 mins):Health News:The 25th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:A Proposed Order Has Been Submitted in A Class Action Law Suit Brought Over Flushmate Toilets, Parker Waichman Announces 2Health News:A Proposed Order Has Been Submitted in A Class Action Law Suit Brought Over Flushmate Toilets, Parker Waichman Announces 3Health News:High Quality 1997-2006 JEEP Wrangler TJ Leather Seat Covers From Popular Supplier Lseat.com 2Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 2Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 3Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 4Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 5Health News:Color Me Launches With Ulta Beauty Revolutionary Makeup Application Device Gets Women Flawless in a Flash 2Health News:Color Me Launches With Ulta Beauty Revolutionary Makeup Application Device Gets Women Flawless in a Flash 3
... a story that continues,to captivate millions of Americans ... transplants, golfer and double heart transplant,recipient Erik Compton ... as he pursues his quest to qualify for ... in Brooksville, Florida., (Photo: http://www.newscom.com/cgi-bin/prnh/20081112/CLW035 ...
... Quantum Group,Inc. (Amex: QGP ) (http://www.QuantumMD.com ... of a scheduled presentation to be,delivered at Paulson ... J. Guillama later this morning, announced today that,it ... 3,650 using the community,health systems (CHS) established by ...
... Infection, LANSING, Mich., Nov. 12 For those ... and flu season, there,s yet another reason to,choose cherries, ... typical flu vaccine, a new study suggests quercetin, a ... in a,variety of fruits and vegetables, including tart cherries, ...
... an early,stage company developing an implantable neuromodulation system ... has closed a licensing,and financing deal, led by ... Existing investor, Greatbatch, Inc. (NYSE: GB ), ... that will provide between,$11 million and $13.5 million ...
... High-Quality Emergency,Healthcare to Rural Areas, NEW YORK, ... announced that it has been selected by Ameya,Preserve ... supplier for each,of the 300 new homes built ... the first of its kind in the United ...
... is facing a medical liability crisis which has,resulted in ... Pacific Research Institute (a not for profit, nonpartisan,organization), was ... total,cost of tort litigation in our country. They have ... due to lawsuit abuse totals $589,billion each year., ...
Cached Medicine News:Health News:Millions Follow Erik Compton's Quest to Win a PGA TOUR Card and Build Awareness for Organ Donation 2Health News:Millions Follow Erik Compton's Quest to Win a PGA TOUR Card and Build Awareness for Organ Donation 3Health News:The Quantum Group Announces Continued Growth of Patient Base and Preliminary Revenue Guidance 2Health News:The Quantum Group Announces Continued Growth of Patient Base and Preliminary Revenue Guidance 3Health News:The Quantum Group Announces Continued Growth of Patient Base and Preliminary Revenue Guidance 4Health News:New Research Shows Specific Antioxidant, Found in Cherries, May Boost the Body's Defenses Against the Flu 2Health News:Intelect Medical Closes $11 Million in Funding from Boston Scientific and Greatbatch for Stroke and TBI Recovery Clinical Trials 2Health News:Intelect Medical Closes $11 Million in Funding from Boston Scientific and Greatbatch for Stroke and TBI Recovery Clinical Trials 3Health News:Intelect Medical Closes $11 Million in Funding from Boston Scientific and Greatbatch for Stroke and TBI Recovery Clinical Trials 4Health News:SwiftMD to Provide Telemedicine Services to New Montana Development 2Health News:SwiftMD to Provide Telemedicine Services to New Montana Development 3Health News:How Texas Cured Its Doctor Shortage and Became a Model for Healthcare Reform 2Health News:How Texas Cured Its Doctor Shortage and Became a Model for Healthcare Reform 3
Multi-frequency, HST, linear transducer with a longer (60mm) footprint. Available with puncture adapter and water path. This transducer incorporates ALOKAs exclusive Hemispheric Sound Technology and ...
Multi-frequency, Super High Density, linear transducer with a longer (60mm) footprint. Available with puncture adapter and water path....
... high frequency (13Mhz) ... and superficial imaging. ... Hemispheric Sound Technology ... This multi-frequency transducer ...
This versatile convex array abdominal transducer is multi-frequency, offering 5 levels of fundamental frequencies in addition to 4 settings of Harmonic frequencies. This transducer provides superb im...
Medicine Products: